RecruitingNCT06413212

Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing


Sponsor

Liu Huang

Enrollment

55 participants

Start Date

Aug 4, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy.


Eligibility

Min Age: 18 Years

Inclusion Criteria9

  • to 75 years old, regardless of gender.
  • Score of nutrition risk screening 2002 (NRS2002) is less than 3, NRS20023.
  • Advanced and unresectable malignancy confirmed by biopsy diagnosis.
  • Able to tolerate anti-tumor treatment, and without serious cardiopulmonary and other underlying diseases.
  • Score of eastern cooperative oncology group (ECOG) is not higher than 2, ECOG≤2.
  • Anticipated survival exceed six months.
  • At least one measurable lesions (according to RECIST 1.1)
  • Resistance or intolerance to standard therapy regimens.
  • Signed informed consent form voluntarily.

Exclusion Criteria7

  • Pregnant or lactating women.
  • Have Participated other clinical trials in six months.
  • Severe liver dysfunction.
  • Severe renal dysfunction.
  • Patients with cognitive disorder, mental diseases and terrible compliance.
  • Allergic to known chemotherapeutic agents.
  • Other circumstance not suitable to participate in this trial determined by investigators.

Interventions

DIAGNOSTIC_TESTPatient-derived tumor-like cell clusters (PTC) drug sensitivity testing.

Fresh malignant effusion samples were collected from advanced malignancy patients for PTC drug sensitivity testing, then assess the accuracy of this diagnostic test by combination and analysis with final clinical outcome.


Locations(1)

Tongji Hospital

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06413212


Related Trials